Cor Vasa 2004, 45(9):435-438

Albumin cobalt binding capacity-a test for diagnosing myocardial ischemia. Potential clinical uses and practical experience

David Stejskal^*, Bořek Lačňák, Renata Juráková, Jitka Prošková, Sylva Adamovská, Gabriela Ožanová, Radka Ochmanová

Oddělení laboratorní medicíny a Interní oddělení, Nemocnice Šternberk, Šternberk, Česká republika

The commonly used laboratory markers of coronary injury in individuals developing acute coronary syndrome (ACS) are not myocardial ischemia-specific and are not helpful unless irreversible myocardial injury has occurred. Recently, there has been debate on the need for a laboratory test capable of satisfactory identification of individuals with myocardial ischemia and symptoms typical of coronary heart disease (CHD) versus those free of CHD.
Several papers have been published since 1994 addressing albumin cobalt binding (ACB) capacity, reporting unique diagnostic sensitivity and specificity of this test for estimating the presence of myocardial ischemia. The test was approved by the Food and Drug Administration (FDA) in February 2003 for early ACS diagnosis. The paper provides a list of present hypotheses, clinical trials, and initial early experience with determining this marker.

Keywords: Acute coronary syndrome; ACB; Laboratory myocardial injury markers

Published: September 1, 2004  Show citation